This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Emerging venture managers increasingly value smaller family office commitments over large ...

The much-anticipated Lp(a)HORIZON trial testing whether the novel drug pelacarsen can improve cardiovascular outcomes by decreasing lipoprotein(a) levels has failed to meet its primary endpoint.

Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

Please provide your email address to receive an email when new articles are posted on . Pelacarsen did not reduce cardiovascular events in patients with elevated lipoprotein(a) compared with placebo.

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This voice experience is generated by AI. Learn more. This ...

The result calls into question other late-stage trials testing Lp(a)-lowering drugs from the likes of Amgen and Eli Lilly. (iStock / Getty Images Plus) Novartis’ Ionis-partnered drug designed to lower ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Many people who face a heightened ...

Add Yahoo as a preferred source to see more of our stories on Google. Image via Jerritt Clark/Getty Images for Neon Carnival Tyga has no reservations about the use of ...

Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal growth ...

Black Bear Value Fund, LP (the “Fund”) returned -3.6% in June and +1.5% YTD. The S&P 500 returned -1.0% in June and +10.2% YTD. We remain heavily invested across the energy and commodity complex. We ...